Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Open accessThe DOI matches its Crossref record; 41 of the 51 references it cites were found in a registry or an index.
Abstract
Significance: Glucagon-like peptide-1 receptor agonists have become established as a leading class of diabetes medications. However, these peptide-based drugs are administered by subcutaneous injection or, in one case, by a complex oral dosing regimen. We now report the discovery of LY3502970, a potent and selective small-molecule GLP-1R agonist. LY3502970 exhibits preclinical pharmacology equivalent to a marketed injectable GLP-1R agonist and possesses pharmacokinetic properties compatible with oral dosing in humans. Cryoelectron microscopy (cryo-EM) studies reveal an ECD-driven receptor binding mode for LY3502970 that provides a favorable pharmacological profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2. Trp33ECD mediates key interaction with LY3502970 and the surrounding region. (A) Amino acid sequence comparison of the ECD regions for GLP-1Rs of different species. (B) LY3502970 increases cAMP accumulation in HEK293 cells expressing a chimeric form of the mouse GLP-1R (domains shown in green) where the N-terminal 142 residues have been replaced by the corresponding region of the human GLP-1R (domains shown in blue). (C) Mutation of Ser33ECD to Trp33ECD in the mouse GLP-1R enables LY3502970 to stimulate receptor-induced cAMP accumulation, while the reciprocal mutation (D) in the human GLP-1R abolishes compound function. The chimera and mutant data are presented as the mean ± SD of three independent experiments. (E) Trp33ECD interacts with LY3502970 and residues on TM2, ECL1, and ECL2. Residues and ligands are shown by sticks except Trp33ECD, which is also shown by spheres. Hydrogen bonds are indicated by dashed lines. (F) GLP-1R ECD orientation in the LY3502970 bound structure stabilized by aromatic interactions with ECL1. (G) The unique ECD orientation of ECD in the LY3502970 bound structure as a result of the unique Trp33ECD position. The structures of GLP-1R bound to LY3502970 (7TM in green, ECD in blue green, LY3502970 in magenta), GLP-1 (yellow, PDB ID code 6VCB), and peptide 5 (gray, PDB ID code 5NX2) are aligned. Trp33ECD is shown by a stick. Other peptide bound GLP-1R structures (GLP-1, PDB ID code 5VAI; ExP5, PDB ID code 6B3J) are not shown here, but their ECD orientations are very similar to GLP-1 bound structure 6VCB in yellow. (H and I) Competitive inhibition of [125I]GLP-1(7-36) binding to membranes isolated from cells expressing the human GLP-1R (H) or human W33S GLP-1R (I). Data are represented as the mean ± SD of three independent experiments.](https://figures.cochat.ai/paper-figures/acc41917547f432fb9ba49113ec198cd/structural-basis-for-glp-1-receptor-activation-by-ly3502970-an-orally-active-figure-2.jpg)


![Fig. 5. LY3502970 enhances glucose-stimulated insulin secretion and reduces food consumption in cynomolgus monkeys. (B–E) Effects of LY3502970 in IVGTT experiments. (A) Schematic diagram of the IVGTT procedure in anesthetized cynomolgus monkeys. Dosing of LY3502970 or exenatide was performed by manual bolus injection, followed by continuous infusion for 80 min. Forty minutes after initiating dosing of vehicle or the drug, glucose was administered intravenously. (B and C) Effect of LY3502970 (B) or exenatide (C) on blood glucose levels. (D and E) Effect of LY3502970 (D) or exenatide (E) on serum insulin levels. Data are represented as the mean ± SEM (n = 7). Significantly different from vehicle 1 or vehicle 2 by Dunnett’s test at *P < 0.025 and **P < 0.005 (one tailed), respectively. Vehicle 1: PEG400/PG/Gly NaOH buffer (pH 9), vehicle 2: 0.05% Tween80 PBS. (F and G) Mean food consumption following administration of LY3502970 (F) or exenatide (G). Cynomolgus monkeys were administered LY3502970, exenatide, or vehicle once daily for 5 d with a 2 d recovery period using an 8 × 5 cross-over design. Food consumption during the 90 min period after feeding was measured. Data are represented as the mean ± SEM (n = 8). Significantly different from the vehicle group by Dunnett’s test at **P < 0.005 (one tailed). Vehicle: dimethyl sulfoxide (DMSO)/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + 0.05% Tween80 PBS [s.c.], LY3502970: LY3502970 [p.o.] + 0.05% Tween 80 PBS [s.c.], exenatide: DMSO/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + exenatide [s.c.].](https://figures.cochat.ai/paper-figures/a9b9ab625235418ca4ecc2d8317f67c4/structural-basis-for-glp-1-receptor-activation-by-ly3502970-an-orally-active-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More specifically, orforglipron is a potent partial GLP-1 RA which is biased towards G-protein activation over to β-arrestin recruitment at the GLP-1 receptor [23].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, orforglipron demonstrated a terminal half-life of 29-49 h in a phase 1b study in people with T2D, which allows once-daily oral dosing [25,28].”
From Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous report, treatment with orforglipron was found to promote glucose-dependent insulin secretion after a glucose challenge [25].”
From Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Orforglipron is an orally administered, non-peptide GLP-1 receptor agonist that can be taken once daily. However, it binds differently to the GLP-1 receptor compared to native GLP-1, thereby inducing G-protein activation rather than beta-arrestin recruitment [107].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [107]
Experimental — accuracy not yet measuredIn the citing paper
“As a small molecule, orforglipron is chemically stable in the acidic gastric environment and is not a substrate for proteolytic enzymes such as dipeptidyl peptidase-4, enabling efficient absorption from the gastrointestinal tract after oral administration and eliminating the need for absorption enhancers or complex formulation strategies that are required for oral peptide GLP-1 therapies [33,34,35”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [33]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 1×
“This starting model was then subjected to iterative rounds of manual and Real Space Refinement in Coot (47, 48) and Phenix (49), respectively.”
MethodGuide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
Zheng, S. Q., Palovcak, E., Armache, J.-P., Verba, K. A., Cheng, Y., & Agard, D. A. (2017) · Nature Methods · doi:10.1038/nmeth.4193 · Cited by 7,777 · cited 2×
“S. Q. Zheng et al., MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy.”
MethodPHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
New tools for automated high-resolution cryo-EM structure determination in RELION-3
Zivanov, J., Nakane, T., Forsberg, B. O., Kimanius, D., Hagen, W. J., Lindahl, E., & Scheres, S. H. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,621 · cited 1×
“Bayesian polishing and CTF refinement (46) were applied to further improve the map, resulting in a 3.”
MethodMolProbity: More and better reference data for improved all‐atom structure validation
Williams, C. J., Headd, J. J., Moriarty, N. W., Prisant, M. G., Videau, L. L., Deis, L. N., Verma, V., Keedy, D. A., Hintze, B. J., Chen, V. B., et al. (2018) · Protein Science · doi:10.1002/pro.3330 · Cited by 4,599 · cited 1×
“The final model was visually inspected for general fit to the map, and geometry was further evaluated using Molprobity (50).”
MethodGctf: Real-time CTF determination and correction
Zhang, K. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.11.003 · Cited by 3,537
Guide for the Care and Use of Laboratory Animals: Eighth Edition -- Tamil Version
Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Studies, D. O. E. A. L., & National Research Council (2011) · National Academies Press eBooks · doi:10.17226/25801 · Cited by 1,118
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 3×
“As an alternative approach, nonpeptide agonists could offer more standard drug formulations with simpler dosing practices, which would be especially beneficial for T2DM patients who often require additional daily medications.”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906 · cited 1×
“Exenatide is equipotent with native GLP-1 for activating the GLP-1R (6) and displays beneficial effects on glucose control and body weight reduction at plasma concentrations in the 40 to 70 pmol/L range (7, 8).”
BackgroundKnudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundNeubig, R. R., Spedding, M., Kenakin, T., & Christopoulos, A. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.4 · Cited by 665 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundCryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., et al. (2017) · Nature · doi:10.1038/nature22394 · Cited by 576 · cited 6×
“In the cryo-EM structure, the receptor is in an active conformation, exhibiting typical active-state class B GPCR structure features on the intracellular side, similar to other GLP-1R/G protein complex structures (2, 32, 36) (SI Appendix, Fig.”
BackgroundMethodInfluentialSelf-citationTranscellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553 · cited 4×
“Further, the dosing regimen for oral semaglutide is restrictive for patients since drug absorption is significantly affected by food and fluid in the stomach (17).”
BackgroundInfluentialProcessing of Structurally Heterogeneous Cryo-EM Data in RELION
Scheres, S. H. W. (2016) · Methods in Enzymology · doi:10.1016/bs.mie.2016.04.012 · Cited by 549
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundPhase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor–Gs complex
Liang, Y.-L., Khoshouei, M., Glukhova, A., Furness, S. G. B., Zhao, P., Clydesdale, L., Koole, C., Truong, T. T., Thal, D. M., Lei, S., et al. (2018) · Nature · doi:10.1038/nature25773 · Cited by 315 · cited 5×
“In the cryo-EM structure, the receptor is in an active conformation, exhibiting typical active-state class B GPCR structure features on the intracellular side, similar to other GLP-1R/G protein complex structures (2, 32, 36) (SI Appendix, Fig.”
BackgroundInfluentialGlaesner, W., Mark Vick, A., Millican, R., Ellis, B., Tschang, S., Tian, Y., Bokvist, K., Brenner, M., Koester, A., Porksen, N., et al. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1080 · Cited by 305 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundTargeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272 · cited 4×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundInfluentialSmall-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundDevelopment of an antibody fragment that stabilizes GPCR/G-protein complexes
Maeda, S., Koehl, A., Matile, H., Hu, H., Hilger, D., Schertler, G. F. X., Manglik, A., Skiniotis, G., Dawson, R. J. P., & Kobilka, B. K. (2018) · Nature Communications · doi:10.1038/s41467-018-06002-w · Cited by 230 · cited 1×
“This modification does not change any regions on Gas that are involved in receptor coupling or nucleotide binding but allows the coupling to scFv16 to aid stabilization of the complex and cryo-EM structure determination (42).”
BackgroundSelf-citationCrystal structure of the GLP-1 receptor bound to a peptide agonist
Jazayeri, A., Rappas, M., Brown, A. J. H., Kean, J., Errey, J. C., Robertson, N. J., Fiez-Vandal, C., Andrews, S. P., Congreve, M., Bortolato, A., et al. (2017) · Nature · doi:10.1038/nature22800 · Cited by 197 · cited 1×
“These features are common among all active-state GLP-1R structures (2, 32, 36, 41) and may provide further insight into the mechanism of GLP-1R activation by LY3502970.”
BackgroundA nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db mice
Chen, D., Liao, J., Li, N., Zhou, C., Liu, Q., Wang, G., Zhang, R., Zhang, S., Lin, L., Chen, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610173104 · Cited by 169 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundActivation of the GLP-1 receptor by a non-peptidic agonist
Zhao, P., Liang, Y.-L., Belousoff, M. J., Deganutti, G., Fletcher, M. M., Willard, F. S., Bell, M. G., Christe, M. E., Sloop, K. W., Inoue, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1902-z · Cited by 164 · cited 8×
“In the cryo-EM structure, the receptor is in an active conformation, exhibiting typical active-state class B GPCR structure features on the intracellular side, similar to other GLP-1R/G protein complex structures (2, 32, 36) (SI Appendix, Fig.”
BackgroundInfluentialSelf-citationSloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundSelf-citationFull-length human GLP-1 receptor structure without orthosteric ligands
Wu, F., Yang, L., Hang, K., Laursen, M., Wu, L., Han, G. W., Ren, Q., Roed, N. K., Lin, G., Hanson, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14934-5 · Cited by 139 · cited 2×
“Other reports have shown that the ECD exhibits a high degree of flexibility and can adopt multiple open or closed conformations (37).”
BackgroundAutocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Zhang, H., Sturchler, E., Zhu, J., Nieto, A., Cistrone, P. A., Xie, J., He, L., Yea, K., Jones, T., Turn, R., et al. (2015) · Nature Communications · doi:10.1038/ncomms9918 · Cited by 137 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundDavidson, M. B., Bate, G., & Kirkpatrick, P. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1828 · Cited by 125
Calara, F., Taylor, K., Han, J., Zabala, E., Carr, E. M., Wintle, M. E., & Fineman, M. S. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.02.008 · Cited by 99 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundStructural insights into probe-dependent positive allosterism of the GLP-1 receptor
Bueno, A. B., Sun, B., Willard, F. S., Feng, D., Ho, J. D., Wainscott, D. B., Showalter, A. D., Vieth, M., Chen, Q., Stutsman, C., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0589-7 · Cited by 98 · cited 5×
“40 is reminiscent of the interaction mode of a GLP-1R-positive allosteric modulator, LSN3160440 (40) (SI Appendix, Fig.”
BackgroundMethodInfluentialSelf-citationTamura, T., Noda, H., Joyashiki, E., Hoshino, M., Watanabe, T., Kinosaki, M., Nishimura, Y., Esaki, T., Ogawa, K., Miyake, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms13384 · Cited by 83 · cited 4×
“cAMP accumulation, β-arrestin recruitment, and receptor binding assays were performed as previously described (28, 40).”
BackgroundMethodInfluentialSelf-citationKothare, P. A., Linnebjerg, H., Isaka, Y., Uenaka, K., Yamamura, A., Yeo, K. P., de la Peña, A., Teng, C. H., Mace, K., Fineman, M., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008323750 · Cited by 62 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundWatkins, H. A., Au, M., & Hay, D. L. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.005 · Cited by 59 · cited 2×
“These domains play a critical role in class B receptor activation by recognizing the ligand in the initial binding event (1).”
BackgroundHeterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials
Caruso, I., Cignarelli, A., & Giorgino, F. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.07.004 · Cited by 58 · cited 3×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundLucey, M., Pickford, P., Bitsi, S., Minnion, J., Ungewiss, J., Schoeneberg, K., Rutter, G. A., Bloom, S. R., Tomas, A., & Jones, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100991 · Cited by 55 · cited 4×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundInfluentialOral semaglutide for the treatment of type 2 diabetes
Hedrington, M. S., & Davis, S. N. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1552258 · Cited by 44 · cited 2×
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundGjesing, A. P., Ekstrøm, C. T., Eiberg, H., Urhammer, S. A., Holst, J. J., Pedersen, O. B., & Hansen, T. F. (2012) · Diabetologia · doi:10.1007/s00125-012-2484-6 · Cited by 33
Jun, L. S., Showalter, A. D., Ali, N., Dai, F., Ma, W., Coskun, T., Ficorilli, J. V., Wheeler, M. B., Michael, M. D., & Sloop, K. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093746 · Cited by 32 · cited 3×
“Therefore, experiments in mice expressing the human GLP-1R were employed to investigate the in vivo efficacy of LY3502970 (33).”
BackgroundMethodSelf-citation
Research works printed but not linked: 1
- T. Nguyen, Drug structures displayed for the first time in Orlando. Chem. Eng. News (2019).
Cited by
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“More speci fi cally, orforglipron is a potent partial GLP-1 RA which is biased towards G-protein activation over to β -arrestin recruitment at the GLP-1 receptor [23].”
Metadata
- Authors
- Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., Kobilka, T. S., Coghlan, M. P., Willard, F. S., Kawabe, Y., Kobilka, B. K., & Sloop, K. W.
- Affiliations
- Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
- ConfometRx (United States) (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Suzuki, Yoshiyuki
- Kobilka, Brian K.
- Sloop, Kyle W.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-11-11
- Volume
- 117
- Issue
- 47
- Pages
- 29959-29967
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7703558
- OpenAlex
- W3099724881
- Cited by
- 231
- References
- 51
- Citations by year
- 2026: 68 · 2025: 53 · 2024: 44 · 2023: 30 · 2022: 19 · 2021: 15 · 2020: 2
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, class B G protein-coupled receptors, receptor structure, partial agonism, biased signaling, G protein activation, beta-arrestin, oral antidiabetic drugs, type 2 diabetes, insulin secretion, blood glucose reduction, non-human primates
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Protein Domains, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Aminopyridines, Animals, Benzamides, Humans, Hypoglycemic Agents, Macaca fascicularis, Male, Mice, Transgenic, Models, Molecular, Species Specificity, Swine, Tryptophan, Mutagenesis, Site-Directed, Anti-Obesity Agents, Cryoelectron Microscopy, Mice, Rats, Incretins, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.